In addition to iSQ, Related Beal owns and has repositioned 27 Drydock, a 286,000-square-foot R&D building, and 451 D Street, a 477,000-square-foot lab and office property in the Seaport District. Special Note Regarding Forward-looking Statements. We see a substantial opportunity to transform the treatment paradigm for type 1 diabetes, a specialty disease cared for by endocrinologists, both by advancing the development and manufacturing of the cells themselves, as well as through the highly innovative cell/device combination.”, “The therapeutic approach pioneered by Semma has the potential to address the causal human biology of type 1 diabetes, a serious disease inadequately controlled by existing therapies. Related Beal recently acquired 7 Elkins, the 60,000-square-foot home to Integra LifeSciences in South Boston, as well as 244-284 A Street along the Fort Point Channel, where substantial lab space is planned. “The tremendous demand we’ve seen from leading biotech companies across all our developments in the neighborhood is a testament to the Seaport’s vibrant business community of forward-thinking companies and surrounding live, work, play environment that is attracting world-class science and engineering talent to South Boston,” said Stephen Faber, executive vice president at Related Beal. About Vertex Pharmaceuticals Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. In addition, we have a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus. Corporate Headquarters Visit The Vertex Global Website. Vertex is consistently recognized as one of the industry's top places to work, including nine consecutive years on Science magazine's Top Employers list and top five on the 2019 Best Employers for Diversity list by Forbes. Scientists from Vertex and Genomics will work closely together to Beyond CF, we have a robust pipeline of investigational small … outcomes. Vertex innovation programs bring together the brightest minds to strike at the core of serious diseases. The powerful idea which Are they going to do it right?". Peter Donnelly FRS, Founder and Chief Executive Officer, Genomics plc. Private Securities Litigation Reform Act of 1995, including, without Vertex creates new possibilities in medicine to cure diseases and improve people's lives. The Genomics engine is the largest of its kind in the but in biomarker selection and patient stratification,” said Professor